Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Continuing Claims Hit Highest Since Nov 2021
11:30am, Thursday, 08'th Aug 2024
It's a big day for Wall Street as the much-awaited Jobless Claims numbers are out, which could be a major factor in market moves for the rest of the week. Right now, stock futures are climbing up as t
Eli Lilly raises forecast after boost in Zepbound, Mounjaro sales
11:07am, Thursday, 08'th Aug 2024
Eli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.
Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter
10:52am, Thursday, 08'th Aug 2024
Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.
Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics
10:35am, Thursday, 08'th Aug 2024
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street esti
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
07:49am, Thursday, 08'th Aug 2024
CNBC's Angelica Peebles joins 'Squawk Box' to break down the company's quarterly earnings results.
Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar
07:21am, Thursday, 08'th Aug 2024
Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts' expectations in the face of growing competition in the lucrat
Blockbuster Drugs Drive Eli Lilly's Strong Q2 Performance
07:10am, Thursday, 08'th Aug 2024
Eli Lilly reports Q2 EPS of $3.92, exceeding expectations. Revenue reaches $11.30 billion, driven by strong drug sales.
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
06:57am, Thursday, 08'th Aug 2024
Eli Lilly reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight l
Eli Lilly's stock leaps after big earnings beat, boosted by strength in Mounjaro and Zepbound sales
06:56am, Thursday, 08'th Aug 2024
Shares of Eli Lilly & Co. LLY, -2.65% shot up 8.5% in premarket trading Thursday, after the drug maker reported second-quarter earnings that rose well above forecasts, boosted by strength in its diabe
Eli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billion
06:51am, Thursday, 08'th Aug 2024
Eli Lilly on Thursday raised its annual profit forecast and sales of its popular weight-loss drug Zepbound crossed $1 billion for the first time in a quarter.
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion
06:45am, Thursday, 08'th Aug 2024
Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%.
Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly
05:00am, Thursday, 08'th Aug 2024
MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs proudly unveils LLYX, the world's first single-stock leveraged ETF for Eli Lilly. LLYX offers retail investors 2X daily long leveraged exposure t
Here's Why Eli Lilly Stock Dropped 12% Last Month
01:04am, Thursday, 08'th Aug 2024
A rival pharmaceutical company released promising clinical trial results from a weight-loss treatment. Eli Lilly is one of two companies dominating the obesity drug market right now.
Eli Lilly Reports Earnings Thursday Amid a Stock Slump
04:30pm, Wednesday, 07'th Aug 2024
Investors will be looking for updates on Zepbound's rollout, and projections for when supply shortages in the U.S. might end.
Eli Lilly: Bearish Signals Loom Over Weight Loss Stock Ahead Of Q2 Earnings
03:28pm, Wednesday, 07'th Aug 2024
Eli Lilly and Co LLY will be reporting its second-quarter earnings on Thursday. Wall Street expects $2.70 in EPS and $9.9 billion in revenues as the company reports before market hours.
